PIPELINE
OUR AlloCAR T PRODUCT PIPELINE TARGETS A VAST ARRAY OF TUMOR TYPES AND AUTOIMMUNE INDICATIONS
| Target | Program | Trial | Study Population | Discovery | IND-enabling | Phase 1 | Phase 21 | Approved | Designation |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic Malignancies | |||||||||
| CD19(Key Program) | Cemacabtagene ansegedleucel (cema-cel) | ALPHA3 | 1L Consolidation LBCL | Development stage: Phase 2 | FTD RMAT |
||||
| CD70 | ALLO-316Dagger-enabled | CD70+ Heme Malignancies | Development stage: IND-enabling | ||||||
| Unnamed | Dagger-enabled | Unnamed | Development stage: Discovery | ||||||
| Solid Tumors | |||||||||
| CD70(Key Program) | ALLO-316Dagger-enabled | TRAVERSE | r/r RCC | Development stage: Phase 1 | FTD RMAT |
||||
| CD70 | ALLO-316Dagger-enabled | Other Solid Tumors | Development stage: IND-enabling | ||||||
| DLL3 | ALLO-213 | SCLC & Neuroendocrine tumors | Development stage: IND-enabling | ||||||
| Claudin 18.2 | ALLO-182 | Gastric & Pancreatic | Development stage: IND-enabling | ||||||
| Unnamed | Dagger-enabled | Multiple unnamed targets | Development stage: Discovery | ||||||
| Autoimmune Disease | |||||||||
| CD19/ |
ALLO-329Dagger-enabled | RESOLUTION | Rheumatology Disorders | Development stage: Phase 1 | FTD | ||||
¹Phase 2 designed to be registrational
DATABRIEF
The DataBrief video series highlights the latest clinical findings from our investigational allogeneic CAR T cell (AlloCAR T) products.
The pivotal Phase 2 ALPHA3 study takes advantage of cema-cel as a one-time, off-the-shelf treatment that can be administered immediately upon discovery of minimal residual disease (MRD) following six cycles of R-CHOP or other chemoimmunotherapy, positioning it to become the standard “7th cycle” of frontline treatment available to all eligible LBCL, inclusive of DLBCL patients with MRD.
-
Episode 1: The ALPHA3 Study
-
Episode 2: Expanding Use of CAR T in Community Cancer Centers
-
Episode 3: Leveraging Investigational MRD Testing
ASCO 2023 – Allogene presented long-term follow up data from the Phase 1 ALPHA/ALPHA2 trials of ALLO‑501/501A demonstrating for the first time the potential of allogeneic CD19 CAR T to induce durable complete remissions in relapsed/refractory large B-cell lymphoma (r/r LBCL) at a rate similar to approved autologous CD19 CAR T therapies.
-
Episode 1: ALLO-501/501A Safety & Tolerability
-
Episode 2: ALLO-501/501A Response & Durability
ASCO 2025
At the 2025 ASCO Annual Meeting, Allogene Therapeutics presented updated Phase 1 data from the TRAVERSE trial of ALLO-316, an allogeneic CAR T product for advanced renal cell carcinoma (RCC). ALLO-316 is the first and only allogeneic CAR T product to show promise in treating solid tumors.
-
Episode 1: ASCO 2025
DOWNLOAD PRESENTATION – ASCO 2025 (PDF)
SITC/IKCS 2024
We shared new data on ALLO-316, our investigational AlloCAR T product candidate for treating CD70-positive advanced or metastatic clear cell renal cell carcinoma (RCC). Results from the Phase 1 TRAVERSE trial highlight the potential of our allogeneic CART therapy to address the unmet needs of adults with CD70-positive RCC who have exhausted standard treatment options.
-
Episode 1: SITC/IKCS 2024
-
Episode 2: SITC/IKCS 2024
DOWNLOAD PRESENTATION – SITC/IKCS 2024 (PDF)
AACR 2023
We presented early findings from the Phase 1 TRAVERSE trial evaluating the safety, tolerability, and activity of ALLO-316, an investigational AlloCAR T™ product candidate for the treatment of CD70 positive advanced or metastatic clear cell renal cell carcinoma (RCC).
-
Episode 1: The TRAVERSE Study
-
Episode 2: The Dagger™ Technology Effect
-
Episode 3: Safety Profile of ALLO-316
-
Episode 4: TRAVERSE Case Studies
ALLOGENE’S EXPANDED ACCESS POLICY
“Expanded Access” refers to the use of an investigational product outside of a clinical trial for potential treatment of a serious or life-threatening condition. Allogene Therapeutics is developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for patients with blood cancers, solid tumors and autoimmune disease. Consistent with our commitment to bring innovative, safe, and effective products to patients, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our products broadly available as quickly and safely as possible. Participation in one of our clinical trials is the best and preferred route to access these investigational products. Allogene does not currently have any active Expanded Access protocols nor do we currently provide access to our investigational products on an Expanded Access basis. We encourage patients interested in our investigational products to learn more about our ongoing studies by visiting clinicaltrials.gov.
Treating physicians may request information about Allogene’s Expanded Access policy by contacting our clinical trials team:
By phone
415-604-5696
By email
clinicaltrials@allogene.com
Allogene will respond to inquiries within 5 business days from receipt.
In the event Allogene decides to consider making one or more of its investigational candidates available for patients who have a serious or life-threatening condition through an Expanded Access program, general criteria to be considered may include: availability of alternative products, the potential risks and benefits to the patient, adequate supply, and potential interference with Allogene’s ongoing clinical trials. All requests would be evaluated on a case-by-case basis in a fair and equitable manner.
This policy shall not serve as a guarantee of access to any specific investigational candidates by any individual patient. Allogene reviews its policies from time to time to ensure conformity with applicable laws and regulations. We reserve the right to revise this policy at any time.